Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Pharm Res. 2011 Jun 15;28(10):2599–2609. doi: 10.1007/s11095-011-0489-3

Fig. 1.

Fig. 1

Schematic diagram (a), photographic image (b), and schematic cross-sectional diagram (c) of a mucoadhesive patch comprising drug (fenretinide/Eudragit® RL PO with or without solubilizers), adhesive (HPMC 4KM: polycarbophil (3:1), and backing (Tegaderm™ adhesive film) layers.